Charles River Laboratories
251 Ballardvale Street
About Charles River Laboratories
About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.
With over 11,000 employees within 70 facilities in 18 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2016, revenue increased by 23.3% to $1.68 billion from $1.36 billion in 2015.
At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~70% of the drugs approved by the FDA in 2016.
For more information, please visit www.criver.com.
Equal Employment Opportunity
Charles River Laboratories, Inc. is an Equal Opportunity Employer M/F/Disabled/Vet
342 articles with Charles River Laboratories
There were a number of major companies reporting their second-quarter financials for the year. Here’s a look at five of the bigger announcements this week.
Charles River Laboratories International, Inc. reported its results for the second quarter of 2019.
Charles River Laboratories International, Inc. will release second-quarter 2019 financial results on Wednesday, July 31st, before the market opens.
Charles River Laboratories International, Inc. announced the planned opening of the Charles River Accelerator and Development Lab in South San Francisco in early 2020.
Contract research organizations may not seem as appealing as working in R&D for a big pharma company or being in on the ground floor of a biotech startup, but it can have a lot of advantages—including plenty of career opportunities.
Charles River Laboratories International, Inc. announced that it will present at two upcoming investor conferences
Andrew Douthwaite, chief technology officer for Colorado-based VirtualArmour, a cybersecurity company, told BioSpace that biotech and pharma companies are desirable targets for hackers and cyber thieves due to the value of the intellectual property.
Access to Resero’s TurboToxicology™ will provide faster delivery of high-quality toxicology reports
Charles River Laboratories International, Inc. reported its results for the first quarter of 2019.
AstraZeneca announced a long-term collaboration deal with BenevolentAI, a UK-based company focused on combining computational medicine and advanced artificial intelligence.This deal only marks one of the most recent AI team-ups announced in the biopharma industry.
The company disclosed the data breach in a filing with the U.S. Securities and Exchange Commission on Tuesday. The hacking occurred in March and the company said the data of about 1 percent of its total number of clients was compromised.
Charles River Laboratories International, Inc. announced that it has completed the previously announced acquisition of Citoxlab for €448 million in cash, subject to customary closing adjustments.
A conference call has been scheduled to discuss this information on Tuesday, May 7th, at 8:30 a.m. ET.
Behind every patient stands thousands of scientists and researchers collaborating to develop life-saving drugs. Jenne’s story highlights the importance of that work.
More job cuts are coming to California life science companies. Charles River Labs and Janssen are both making cuts as they reprioritize their businesses, according to Worker Adjustment and Retraining Notifications filed with the state of California.
Researchers will highlight work in BRCA-deficient and rare pediatric cancers
Management will present an overview of Charles River’s strategic focus and business developments.
Charles River Laboratories International, Inc. announced that it has signed a binding offer to acquire Citoxlab for €448 million in cash, subject to customary closing adjustments.
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2018 Results and Provides 2019 Guidance
Charles River Laboratories International, Inc. reported its results for the fourth-quarter and full-year 2018 and provided guidance for 2019.
Charles River Laboratories Schedules Fourth-Quarter 2018 Earnings and 2019 Guidance Release and Conference Call
A conference call has been scheduled to discuss this information on Wednesday, February 13th, at 8:30 a.m. ET.